Top News

Allergan Buys MAP Pharmaceuticals

Irvine-based Allergan and MAP Pharmaceuticals said this morning that Allergan has agreed to acquire MAP Pharmaceuticals, in a deal worth approximately $958M. Allergan said it will pay $25.00 per share for publicly held MAP Pharmaceuticals. MAP Pharmaceuticals develops biopharmaceuticals, with its lead product being LEVADEX, an orally inhaled drug under trials for treating migraines in adults.





Latest Headlines

Browse Issues


Keep up with all of the latest Southern California high tech news via email (it's free!)

or Cancel